GlassScriptPhysician profile
Adam B Lowe
NPI 1184624025
$8,838.53
in general payments reported to CMS, 2019-2025
30 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $164 · 2021: $1,632 · 2022: $2,361 · 2023: $2,163 · 2024: $1,190 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,987.32 | 2019-2025 | |
| Celgene Corporation | $848.46 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $794.41 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $639.34 | 2019-2025 | |
| Janssen Biotech, INC. | $552.26 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Ferring Pharmaceuticals INC. | $363.19 | 2021-2024 | Cimzia, Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $275.00 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $273.17 | 2019-2024 | Linzess |
| Olympus America INC. | $259.90 | 2021-2022 | |
| Redhill Biopharma INC. | $226.04 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Boston Scientific Corporation | $209.53 | 2021-2022 | |
| Qol Medical, LLC | $188.76 | 2021-2025 | Sucraid |
| Gilead Sciences, INC. | $157.18 | 2023-2025 | |
| Daiichi Sankyo INC. | $144.66 | 2021-2023 | Injectafer |
| Genzyme Corporation | $134.90 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $118.33 | 2022-2025 | Dupixent |
| Lucid Diagnostics INC. | $112.23 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $104.54 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $102.77 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $66.99 | 2021-2023 | Ocaliva |
| Medtronic, INC. | $56.50 | 2022-2023 | Interstim |
| Abbott Laboratories | $48.05 | 2021 | |
| Lilly USA, LLC | $31.15 | 2024-2025 | Omvoh |
| W. L. Gore & Associates, INC. | $28.05 | 2022-2023 | Gore Cardioform Septal Occluder |
| Intuitive Surgical, INC. | $23.33 | 2023 | |
| Allergan, INC. | $22.10 | 2019 | |
| Csl Behring | $20.94 | 2019 | |
| Echosens North America, INC. | $19.07 | 2021 | |
| Intra-Sana Laboratories | $15.91 | 2022 | |
| Braintree Laboratories, INC. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.